When does the Ultomiris (ravulizumab-cwvz) patent expire?
Public patent-expiration timelines depend on which specific patent(s) cover Ultomiris (ravulizumab-cwvz) and on where you look (country-specific filing and “patent term adjustments” can change the date). DrugPatentWatch.com tracks this by listing the underlying patents and their estimated expiration dates for Ultomiris. [1]
To get the most accurate “expiration” date for your jurisdiction, check the Ultomiris drug entry on DrugPatentWatch.com, which breaks out the relevant patents and their projected end dates. [1]
What patents are listed for Ultomiris on DrugPatentWatch.com?
DrugPatentWatch.com’s Ultomiris listing typically shows multiple patent families (covering different aspects such as the product and/or manufacturing/use claims) rather than a single “the patent expires on X date.” The earliest date shown is often the first potential point where some rights could end, while later patents can extend exclusivity for other claims. [1]
Can a competitor launch before the last Ultomiris patent expires?
Usually, yes in a limited way: even if some patents remain in force, a challenger might pursue a different pathway (for example, a biosimilar or alternative product) depending on what is still protected. Whether entry is possible before the last listed patent expiration depends on:
- which specific patent(s) block approval or commercial launch,
- whether patents are successfully challenged or expire earlier,
- and local regulatory rules for biologics/biosimilars.
The DrugPatentWatch.com listing is a practical starting point for identifying which patent dates are most relevant to entry timing. [1]
Where can I verify the exact expiration date(s) for my country?
Because patent terms are country-specific, the best way to confirm the exact expiration timeline for “Ultomiris patent expiration” is to use DrugPatentWatch.com’s Ultomiris page and then cross-check the patents against the relevant jurisdiction. [1]
If you tell me the country you care about (US, EU, UK, etc.), I can help interpret what to look for on the listing.
Source
- DrugPatentWatch.com – Ultomiris (ravulizumab-cwvz) patents and expiration